GRAIL Surges as FDA Panel Backs Its Multi-Cancer Blood Test

GRAIL shares surged this week as it received a major regulatory boost for Galleri, its blood test capable of detecting over 50 types of cancers from a single blood draw. 

On September 23, 2026, an FDA advisory committee voted 10-0 that Galleri is safe and 6-4 that it is effective. Maybe more critical for its future success, however, the panel voted 7-2 that the test’s benefits outweigh its risks for adults 50 years or older. The FDA is not required to follow these decisions made by the committee, but the vote certainly brings Galleri closer to potentially becoming the first FDA-approved multi-cancer detection blood test. 

Investors have already shown positive and enthusiastic feedback to these signs of regulatory support, as GRAIL shares jumped 34% after released FDA briefing documents raised no major safety concerns. 

Galleri works by searching the bloodstream for DNA methylation patterns associated with cancer and predicts where a detected cancer signal originated. Unlike traditional screening methods such as mammograms and colonoscopies, which target individual cancers, Galleri is designed to identify dozens simultaneously, including cancers without established screening programs.

However, there are still some concerns about Galleri’s effectiveness. Earlier in the year, GRAIL conducted a 142,000 person NHS-Galleri trial. The company reported that it failed to meet its primary endpoint of significantly reducing stage III and stage IV cancer diagnoses. After the report, GRAIL shares dropped around 50%. The narrow 6-4 committee vote reflects on some of that lingering uncertainty. 

From a financial perspective, FDA approval could have huge implications for GRAIL. Galleri is already commercially available in the United States with a current price tag of $949. However, Medicare and most insurance plans do not cover it. Despite this, Galleri still managed to generate $136.8 million in revenue in 2025, while first-half 2026 revenue increased another 30%, year over year. FDA approval could help expand insurance coverage and open new markets for Galleri. 

All in all, GRAIL seems to have flipped the script. The company has achieved a ton of positive signs from regulators, putting new possibilities more in reach. While it still faces some concerns over effectiveness, Galleri’s path to the broader cancer-screening market has become a lot clearer.